bmi to qualify for glp 1 How many adults with private health insurance could use GLP-1 drugs What is the qualifying Body
Description
A combined review of phase III clinical tests and 2 outcome analyses revealed a marginally greater (but not significant) risk of GLP-1 receptor agonist pancreatitis relative to alternative treatment results
Zhang Q, Li Q, Liu S, et al
doi: 10.1080/08910600902815553 339 DucrottPSawantPJayanthiV
The results provide quantitative data for the evaluation of new drugs and, optimization of treatment strategies for people with obesity
the dose is the open question
